

BRD4 Protein, Human, Recombinant (His & Flag)

General Information

Synonyms:	MCAP;HUNK1;HUNKI;bromodomain-containing protein 4
Protein Construction:	Glu49-Glu460
Species:	Human
Expression Host:	E. coli
Accession:	O60885
Molecular Weight:	55-60 KDa (reducing condition)
AA Sequence:	Glu49-Glu460

QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	Greater than 90% as determined by reducing SDS-PAGE. (QC verified)
Endotoxin:	< 0.1 ng/μg (1 EU/μg) as determined by LAL test.
Formulation:	Supplied as a 0.2 μm filtered solution of 50 mM HEPES, 200 mM NaCl, 1 mM DTT, 10% Glycerol, pH 7.5.

Preparation and Storage

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

Proteins are shipped with blue ice.

Protein Background

Bromodomain-containing protein 4 (BRD4) is a member of the BET class chromatin reader proteins that bind acetylated histones and play a key role in transcriptional regulation and transmission of epigenetic memory. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. BRD bromodomains serve as recognition motifs for acetylated lysine residues on histones, while the NET domain may function by promoting phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II. Some specific inhibitors of BRD4 that prevent binding to acetylated histones by binding Asn-140 and Asn-433 are promising therapeutic molecules for the treatment of leukemias. BRD4 is a potential therapeutic target in many diseases including breast cancer, AML, multiple myeloma, colon cancer and others.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481